A 2‐year prospective, partially randomized open‐label trial comparing oral alendronate with
intravenous pamidronate therapy in children with OI showed equivalence in increasing total …

INTRODUCTION: Bone mineral density (BMD) and fracture rates in children with
osteogenesis imperfecta (OI) have been shown to improve with bisphosphonate therapy …

Osteogenesis imperfecta (OI) is an inherited disorder characterized by bone fragility and low
bone mass. Low bone density and fracture is a cause of morbidity. Limited data exists on …

Objective. Several studies have reported beneficial effects of bisphosphonates in children
with osteogenesis imperfecta (OI); however, these studies have differed in the protocols they …

Bisphosphonates have been widely administered to children with OI based on observational
trials. A randomized controlled trial of q3m intravenous pamidronate in children with types III …

Bone mineral density and fracture rates in children with osteogenesis imperfecta improve
with intravenous bisphosphonates. The efficacy of oral bisphosphonates has not been …

Cyclical intravenous bisphosphonate therapy is widely used to treat children with
osteogenesis imperfecta (OI), but little is known about long‐term treatment outcomes. We …

Background: Recent studies reported beneficial effect of cyclical intravenous administration
of pamidronate in children and adolescents with osteogenesis imperfecta (OI). However, this …

Cyclical intravenous therapy with pamidronate improves the clinical course in children and
adolescents with osteogenesis imperfecta (OI). In this study, we evaluated the effect of this …

Clinical and histomorphometric outcome was compared between children with OI who had
received pamidronate since infancy and age‐matched patients who had never received …